HOME > Investors > Press Releases
2013-06-18
Completes Patient Enrollment/Administration of VM202-DPN Phase II Clinical Study for the Treatment of Diabetic Peripheral Neuropathy
2017-03-06
2017.02. (IR letter) Business Updates
2015-04-28
US FDA Approves VM202 for Phase III Clinical Study of Diabetic Peripheral Neuropathy (DPN)
2014-11-21
Disclosure of Clinical Trial Entry • Exit (Voluntary Disclosure)
2012-09-24
ViroMed announces final patient enrollment for VM202-PAD phase II clinical trial in US/Korea
11 12 13 14 15 16 17 18 19 20